148 related articles for article (PubMed ID: 18675446)
1. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group.
Garcia AA; Blessing JA; Nolte S; Mannel RS;
Gynecol Oncol; 2008 Oct; 111(1):22-6. PubMed ID: 18675446
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
Garcia AA; Blessing JA; Vaccarello L; Roman LD;
Am J Clin Oncol; 2007 Aug; 30(4):428-31. PubMed ID: 17762444
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of weekly docetaxel for patients with advanced or recurrent cancer of the cervix.
Pearl ML; Johnston CM; McMeekin DS
Gynecol Obstet Invest; 2007; 64(4):193-8. PubMed ID: 17664880
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study.
Fracasso PM; Blessing JA; Molpus KL; Adler LM; Sorosky JI; Rose PG
Gynecol Oncol; 2006 Nov; 103(2):523-6. PubMed ID: 16712905
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4.
Günthert AR; Ackermann S; Beckmann MW; Camara O; Kiesel L; Rensing K; Schröder W; Steiner E; Emons G;
Gynecol Oncol; 2007 Jan; 104(1):86-90. PubMed ID: 16996111
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Plaxe SC; Blessing JA; Husseinzadeh N; Webster KD; Rader JS; Dunton CJ
Gynecol Oncol; 2002 Feb; 84(2):241-4. PubMed ID: 11812081
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Alvarez EA; Brady WE; Walker JL; Rotmensch J; Zhou XC; Kendrick JE; Yamada SD; Schilder JM; Cohn DE; Harrison CR; Moore KN; Aghajanian C
Gynecol Oncol; 2013 Apr; 129(1):22-7. PubMed ID: 23262204
[TBL] [Abstract][Full Text] [Related]
8. A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study.
Grendys EC; Blessing JA; Burger R; Hoffman J
Gynecol Oncol; 2005 Aug; 98(2):249-53. PubMed ID: 15978659
[TBL] [Abstract][Full Text] [Related]
9. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology.
Miller DS; Blessing JA; Drake RD; Higgins R; McMeekin DS; Puneky LV; Krasner CN
Gynecol Oncol; 2009 Dec; 115(3):443-6. PubMed ID: 19804902
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study.
Katsumata N; Noda K; Nozawa S; Kitagawa R; Nishimura R; Yamaguchi S; Aoki D; Susumu N; Kuramoto H; Jobo T; Ueki K; Ueki M; Kohno I; Fujiwara K; Sohda Y; Eguchi F
Br J Cancer; 2005 Oct; 93(9):999-1004. PubMed ID: 16234823
[TBL] [Abstract][Full Text] [Related]
11. Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group.
Moore DH; Blessing JA; Dunton C; Buller RE; Reid GC
Gynecol Oncol; 1999 Dec; 75(3):473-5. PubMed ID: 10600310
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Rose PG; Brunetto VL; VanLe L; Bell J; Walker JL; Lee RB
Gynecol Oncol; 2000 Aug; 78(2):212-6. PubMed ID: 10926805
[TBL] [Abstract][Full Text] [Related]
13. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Covens A; Blessing J; Bender D; Mannel R; Morgan M;
Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study.
Homesley HD; Blessing JA; Sorosky J; Reid G; Look KY
Gynecol Oncol; 2005 Aug; 98(2):294-8. PubMed ID: 15975638
[TBL] [Abstract][Full Text] [Related]
15. Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
Lim JY; Cho JY; Paik YH; Lee DK; Lee SI; Park HJ; Lee SJ; Lee KS; Yoon DS; Choi SH
Oncology; 2007; 73(1-2):2-8. PubMed ID: 18332648
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study.
Takekuma M; Hirashima Y; Ito K; Tsubamoto H; Tabata T; Arakawa A; Itani Y; Furukawa N; Murakoshi H; Takeuchi S
Gynecol Oncol; 2012 Sep; 126(3):341-5. PubMed ID: 22609108
[TBL] [Abstract][Full Text] [Related]
18. Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
Miller DS; Blessing JA; Waggoner S; Schilder J; Sorosky J; Bloss J; Schilder R
Gynecol Oncol; 2005 Jan; 96(1):67-71. PubMed ID: 15589582
[TBL] [Abstract][Full Text] [Related]
19. A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study.
Fiorica JV; Blessing JA; Puneky LV; Secord AA; Hoffman JS; Yamada SD; Buekers TE; Bell J; Schilder JM;
Gynecol Oncol; 2009 Nov; 115(2):285-9. PubMed ID: 19726073
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Modesitt SC; Sill M; Hoffman JS; Bender DP;
Gynecol Oncol; 2008 May; 109(2):182-6. PubMed ID: 18295319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]